You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
SBC: Actinium Pharmaceuticals, Inc. Topic: 102ABSTRACT Despite treatment advances, the prognosis of adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and R/R diffuse large B-cell lymphoma (DLBCL) remains poor. Autologous T- cells modified to express a CD19-targeted chimeric antigen receptor (CAR T-cells) produce durable responses in subgroups of these patients, which has led to FDA approval of two su ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum
SBC: STEM CULTURES LLC Topic: 400Scientific Abstract: The frequent use of fetal bovine serum (FBS) to support cell cultures is challenged by lot-to-lot variability, supply constraints, pathogen contaminants and ethical questions. These issues have increased significance due to the burgeoning use of FBS in cell research and therapy development. FBS has been used for over a century to culture cells, but with the need to define cult ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Improved Treatment of Colorectal Cancer with CF10
SBC: Deep Creek Pharma, LLC Topic: 102PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or metastatic disease (mCRC). However, outcomes remain poor for patients with mCRC and since targeted ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CN-105 Improves Functional Outcome After Intracranial Hemorrhage
SBC: AegisCN LLC Topic: 106Annually, approximately 100,000 patients in the USA suffer from intracerebral hemorrhage (ICH), which is associated with high mortality rates and poor long-term cognitive and physical recovery. At present, no pharmacological therapies have been demonstrated to improve functional outcomes after ICH. However, we have successfully demonstrated that CN-105, a pentapeptide derived from the receptor bin ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
The Assessment of Smart Phone Everyday Tasks (ASSET): A new IADL test for early AD
SBC: RIP ROAD, INC. Topic: NIAProject SummaryImpairment in instrumental activities of daily living (IADL) is a hallmark of Alzheimer’s disease (AD) dementia and a major source of patient and caregiver burden. Similarly to cognitive changes in AD, subtle difficulties in IADL may begin even before the stage of amnestic mild cognitive impairment (MCI). Recently, greater emphasis has been placed on preclinical AD, which consists ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
An Interactive Education Program to Reduce High Risk Behavior in Adolescents
SBC: KLEIN BUENDEL, INC. Topic: NICHDInternet-based TRAC (i-TRAC): Interactive Emotion Regulation Skills Training to Improve AdolescentSexual Health Adolescence is a critical developmental period during which behavioral patterns are formed that have powerful influences on current and future health. This is particularly true for sexual behavior, which is affected by the biological changes of puberty as well as normative developmental ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma
SBC: ROCK IMMUNE LLC Topic: 102Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skinlesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are thetwo most common types of CTCL. Although treatments exist, they are mainly palliative with low response anddurability of response without any cure. The objective response rate rem ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
ARRAY: A novel polymeric mesh for prophylactic antibiotic protection of cardiac implantable electronic devices
SBC: 21MedTech LLC Topic: NHLBIPROJECT SUMMARY 21MedTech, LLC is developing the ARRAYTM antibiotic-loaded envelope to address the need for novel methods to tackle rising rates of infections associated with cardiovascular implantable electronic devices (CIEDs). There were 1.5 million CIEDs implanted in 2011 and that number continues to grow. Between 1% and 4% of implantations result in infection, which have potential for severe ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel recombinant sensors to study histone ubiquitin signaling
SBC: Epicypher, Inc. Topic: 400PROJECT SUMMARYMonoubiquitination (Ub) of histones is an important post-translational modification (PTM) that regulates multiple DNA-related processes including DNA replication, transcription, and repair. Aberrant regulation of histone Ub is strongly linked to the pathogenesis of diverse diseases, including cancer, aging, and inflammation. However, the ability to map the distribution and dynamics ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A Disease-Modifying Protein Therapeutic for the Treatment of COPD
SBC: VERRA THERAPEUTICS LLC Topic: NHLBIPROJECT SUMMARY Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide at 3.23 million (2019), while nearly 400 million suffer its effects. COPD is a heterogeneous, multi-phenotypic disease with lung damage derived from smoking, vaping, cooking, forest fires, pollution, chemical exposure, and numerous occupational hazards (e.g., 1st responders, military, agricul ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health